MAXCYTE INC (MXCT) Stock Price, Quote, News and Overview
NASDAQ:MXCT - Nasdaq - US57777K1060 - Common Stock - Currency: USD
MXCT Quote, Performance and Key Statistics
2.22
-0.06 (-2.63%)
The current stock price of MXCT is 2.22 USD. In the past month the price decreased by -3.48%. In the past year, price decreased by -50.56%.
MXCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.86 | 164.16B | ||
| DHR | DANAHER CORP | 27.5 | 146.60B | ||
| A | AGILENT TECHNOLOGIES INC | 22.83 | 35.02B | ||
| IQV | IQVIA HOLDINGS INC | 14.41 | 28.16B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 30.25 | 25.43B | ||
| WAT | WATERS CORP | 29.63 | 21.00B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 34.21 | 16.32B | ||
| ILMN | ILLUMINA INC | 29.8 | 15.71B | ||
| RVTY | REVVITY INC | 20.59 | 11.96B | ||
| ICLR | ICON PLC | 10.97 | 11.96B | ||
| QGEN | QIAGEN N.V. | 20.93 | 10.42B | ||
| TEM | TEMPUS AI INC | N/A | 9.85B |
Related stock screener links
About MXCT
Company Profile
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Rockville, Maryland and currently employs 114 full-time employees. The company went IPO on 2016-03-29. The company leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. The company also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Company Info
MAXCYTE INC
9713 Key West Avenue,, Suite 400
Rockville MARYLAND US
CEO: Doug Doerfler
Employees: 114
Phone: 13015175556
MAXCYTE INC / MXCT FAQ
What is the stock price of MAXCYTE INC today?
The current stock price of MXCT is 2.22 USD. The price decreased by -2.63% in the last trading session.
What is the ticker symbol for MAXCYTE INC stock?
The exchange symbol of MAXCYTE INC is MXCT and it is listed on the Nasdaq exchange.
On which exchange is MXCT stock listed?
MXCT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MAXCYTE INC stock?
11 analysts have analysed MXCT and the average price target is 7.14 USD. This implies a price increase of 221.62% is expected in the next year compared to the current price of 2.22. Check the MAXCYTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MAXCYTE INC worth?
MAXCYTE INC (MXCT) has a market capitalization of 236.25M USD. This makes MXCT a Micro Cap stock.
How many employees does MAXCYTE INC have?
MAXCYTE INC (MXCT) currently has 114 employees.
What are the support and resistance levels for MAXCYTE INC (MXCT) stock?
MAXCYTE INC (MXCT) has a resistance level at 2.24. Check the full technical report for a detailed analysis of MXCT support and resistance levels.
Is MAXCYTE INC (MXCT) expected to grow?
The Revenue of MAXCYTE INC (MXCT) is expected to grow by 8.8% in the next year. Check the estimates tab for more information on the MXCT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MAXCYTE INC (MXCT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MXCT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MXCT, evaluating the profitability, health, valuation and growth aspects
- MAXCYTE INC (MXCT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MAXCYTE INC (MXCT) Sales and EPS estimates to see what analysts future expectations are.
- MAXCYTE INC (MXCT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MAXCYTE INC (MXCT) Insider and Institutional Ownership to learn about the owners and their transactions.
- MAXCYTE INC (MXCT) Stock Chart to make your own analysis
- MAXCYTE INC (MXCT) Latest news and press-releases to stay up to date.
Does MAXCYTE INC (MXCT) stock pay dividends?
MXCT does not pay a dividend.
When does MAXCYTE INC (MXCT) report earnings?
MAXCYTE INC (MXCT) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of MAXCYTE INC (MXCT)?
MAXCYTE INC (MXCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
What is the Short Interest ratio of MAXCYTE INC (MXCT) stock?
The outstanding short interest for MAXCYTE INC (MXCT) is 3.57% of its float. Check the ownership tab for more information on the MXCT short interest.
MXCT Technical Analysis
MXCT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MXCT. MXCT has a great financial health rating, but its profitability evaluates not so good.
MXCT Financial Highlights
Over the last trailing twelve months MXCT reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS decreased by -14.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.17% | ||
| ROE | -20.96% | ||
| Debt/Equity | 0 |
MXCT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to MXCT. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 0.62% and a revenue growth 8.8% for MXCT